Clinical Trial Update: Trial of Neoadjuvant EndoTAG-1 in Combination With Paclitaxel in HER2-negative Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant trial evaluating EndoTAG-1 in combination with Paclitaxel for HER2-negative breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• EndoTAG-1
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Jules Bordet Institute | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED